💨 Abstract

The psychedelic drugs market is projected to grow at an annual rate of 12.1% through 2030, attracting investors despite risks like paranoia, psychosis, and addiction. Key players include Compass Pathways, MindMed, and GH Research, which offer varying levels of risk and potential reward. Investors must be patient and willing to endure volatility, focusing on market-relevant regulatory milestones and clinical studies with strong academic backing.

Courtesy: WTOP Staff